2025 Innovative Drug & Supply Chain Innovation White Paper
We stand today at a pivotal moment in the era of biopharmaceuticals. Accelerating global health demands, deepening convergence of cutting-edge technologies, and dramatic restructuring of the industrial landscape are shaping our collective future—and China is integrating into this wave of innovation with unprecedented momentum. In 2025, following a period of rational consolidation, China's innovative drug and supply chain industry has entered a phase of value reorientation and structural reinvention. This year has thus become a defining chapter in which Chinese innovation repositions itself within the global healthcare ecosystem.
If one word could capture the essence of China's innovative drug sector in 2025, it would be "divergence." This divergence is reflected in capital allocation: investors no longer fund narratives alone but are channeling resources toward companies with robust technology platforms, clear clinical value, and global potential. It is mirrored in policy evolution: regulators are moving beyond speed-oriented approval to build a comprehensive, lifecycle-oriented support system spanning early R&D to market access. And it is evident in corporate trajectories: a cohort of technically distinguished companies is emerging, securing recognition and partnerships with multinational pharmaceutical firms, while players lacking differentiated competitiveness face increasing pressure to exit.
As a frontline observer and active participant in China's healthcare ecosystem, VCBeat senses that amid this interplay of divergence and refocusing, the core logic of China's innovative pharmaceutical industry has fundamentally shifted. A new era—driven by product strength, platform capability, and global operational excellence—is accelerating into view.
Adhering to principles of independence, objectivity, and professionalism, the VB Insight (VCBeat's research and database platform) has undertaken a systematic review of the innovative drug and supply chain landscape in China during 2025. We have analyzed policy shifts, financing trends, licensing transaction data, and clinical pipeline progress across hundreds of enterprises, complemented by interviews with frontline investors, entrepreneurs, and industry experts—all to capture the true pulse of the industry.
In today's rapidly changing environment, recognizing true value and determining future directions have become crucial challenges for all stakeholders. To address this, VCBeat is launching the "2025 Innovative Drug & Supply Chain Innovation White Paper." This document is grounded in current realities while also focusing on future possibilities, drawing on extensive long-term industry tracking and insights.
The purpose of this White Paper extends beyond documentation and description. We aim to serve as "value discoverers" and "ecosystem connectors," systematically identifying, analyzing, and presenting to the global market those Chinese innovative products, technology platforms, and solutions that have demonstrated true competitiveness amid the waves of divergence.
Core Perspectives
In terms of policy guidance, we systematically reviewed over 300 national and local policies from January to October 2025, particularly nearly 100 technical guidance documents issued by the National Medical Products Administration (NMPA). We observed that the policy environment has shifted from the early-stage principle-based advocacy of "encouraging innovation" to a new phase of systematic and targeted guidance on "how to innovate." This provides a supportive institutional foundation for projects with genuine pioneering capabilities.
Regarding capital allocation trends, we conducted an in-depth analysis of nearly 300 financing rounds and over 200 licensing deals. The data clearly reveals that the underlying logic of capital deployment has fundamentally changed. While the overall volume of primary market financing has become more cautious, funds are increasingly concentrated in mid-to-late-stage projects (Series B and beyond) and cutting-edge fields such as antibody-drug conjugates (ADCs), bispecific antibodies, cell and gene therapy (CGT), and AI-driven drug discovery. At the same time, companies seeking initial public offerings (IPOs) in the secondary market must demonstrate solid clinical progress and clear commercialization prospects to gain investor recognition. In 2025, the total value of China's innovative drug license-out transactions reached a historic high, with deal structures expanding from single-product licenses to deeper collaborative models such as platform technology licensing and the establishment of joint ventures (NewCo).
In evaluating pipeline competitiveness, we performed a detailed analysis of clinical pipeline progress across hundreds of enterprises. The year 2025 marked a period of concentrated validation for both the clinical and commercial value of China's innovative drugs. China-developed ADC and bispecific antibody products gained consecutive regulatory approvals and demonstrated globally leading clinical data at top-tier international academic conferences such as the American Society of Clinical Oncology (ASCO) Annual Meeting. Breakthroughs were also achieved with small-molecule drugs targeting historically "undruggable" targets such as KRAS G12C, alongside significant progress in cell therapies—including chimeric antigen receptor T-cell therapy (CAR-T) and tumor-infiltrating lymphocyte therapy (TIL)—as well as nucleic acid therapeutics. These advances reflect the evolving capability of Chinese companies, transitioning from follow-on innovation to pioneering research and from technology adoption to systematic output.
Based on cross-dimensional analysis and in-depth research across these areas, this White Paper is committed to fulfilling its mission: mapping industry hotspots and trends, identifying high-value sectors and benchmark players, and forecasting future directions and developments. We hope this report serves not only as a thorough review of 2025 but also as a guidepost toward 2026: the future of China's biopharmaceutical industry will be led by enterprises that uphold scientific rigor, focus on innovation, and possess a global perspective.